HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Arcturus Therapeutics in a research note issued on Tuesday, August 11th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of ($0.87) for the quarter, up from their previous forecast of ($0.94). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Arcturus Therapeutics’ Q4 2026 earnings at ($0.76) EPS, FY2026 earnings at ($3.46) EPS, FY2027 earnings at ($3.37) EPS, FY2028 earnings at ($3.31) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $5.63 EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The business had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million.

Several other analysts have also recently issued reports on ARCT. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.25.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $7.60 on Thursday. The company has a market capitalization of $216.01 million, a price-to-earnings ratio of -2.30 and a beta of 2.39. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $24.17. The stock has a 50-day simple moving average of $6.75 and a 200 day simple moving average of $7.39.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Heartland Advisors Inc. bought a new stake in Arcturus Therapeutics in the second quarter valued at $1,474,000. Green Alpha Advisors LLC bought a new position in shares of Arcturus Therapeutics during the second quarter worth about $182,000. Diversify Advisory Services LLC bought a new position in shares of Arcturus Therapeutics during the second quarter worth about $91,000. BlackRock Inc. acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter worth about $17,566,000. Finally, Deutsche Bank AG acquired a new stake in shares of Arcturus Therapeutics in the 2nd quarter worth about $195,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.